Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with Radium-223 in mCRPC (EnzaRadiCate)
NCT02507570Phase 2Completed
- Sponsor
- Carolina Research Professionals
- Start
- Sep 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Carolina Research Professionals. Primary endpoint: Number of participants with adverse events and serious adverse events. Started Sep 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02507570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507570.